ArticleMolecular biology reports2025
Activation of GLP-1 receptors enhances the osteogenic differentiation process of STRO-1-positive BMSCs.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review.Stem cell reviews and reports · 2026Pooled it
- Glucagon-like peptide-1: a critical link between gut microbiota dysbiosis and degenerative musculoskeletal diseases.Gut microbes · 2026Review
- GLP-1 Receptor Agonist and GIP/GLP-1 Receptor Dual Agonist Therapeutics at the Intersection of Alcohol Use Disorder, Obesity, and Cardiometabolic Dysfunction.Biological psychiatry global open science · 2026Review
- Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings.Journal of orthopaedic surgery and research · 2025Article
- Decoding dental mesenchymal stem cells diversity: single-cell transcriptomics maps heterogeneity in molar development.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOsteoporosis is a prevalent metabolic bone disorder, especially in individuals with diabetes. Recent studies suggest that GLP-1 plays a positive role in regulating bone metabolism. However, the impact of GLP-1R on bone marrow-derived mesenchymal stem cells, particularly STRO-1-positive BMSCs, remains unclear. This study aims to investigate the impact of GLP-1R activation on the osteogenic differentiation potential of STRO-1-positive BMSCs. METHODS AND
resultsBMSCs were isolated from the femurs and tibias of Sprague-Dawley rats, characterized by flow cytometry and immunofluorescence. The expression of osteogenic genes(COL-I, OCN, RUNX2) and osteoprotegerin(OPG) was assessed by qPCR and Western blot. Osteogenic differentiation was evaluated by alizarin red and alkaline phosphatase staining. The GLP-1R expression in STRO-1-positive and negative BMSCs was compared. Pharmacological interventions with GLP-1R agonists and antagonists were used to evaluate their effect on osteogenesis. The results show that STRO-1-positive BMSCs exhibited stronger osteogenic potential than STRO-1-negative BMSCs. GLP-1R activation enhanced osteogenesis, with the agonist group displaying the highest mineralization capacity despite showing lower osteogenic gene expression. The control group exhibited the highest gene expression but the weakest mineralization capacity. Furthermore, JNK/ERK mRNA and protein levels were reduced at varying degrees in the experimental groups.
conclusionSTRO-1-positive BMSCs exhibit stronger osteogenic potential, which may be facilitated through GLP-1R activity at varying levels, promoting their differentiation into mature osteoblasts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.